SEC Form 4 · accession 0001179110-17-003751
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald McMahon Ph.D.
Director
Period of report
Mar 1, 2017
Accepted (ET)
Mar 3, 2017 · 9:10 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.001 per shareF1,F2 | Mar 1, 2017 | F | 32,927 | $3.54 | D | 234,429 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On November 28, 2016, in connection with Reporting Person's employment separation with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). 200,517 shares of Common Stock, less Withholdings, will be issued to Reporting Person ratably over 24 months commencing in the first quarter of 2017 and 66,839 shares of Common Stock, less Withholdings will be issued not later than March 15, 2017. The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016.
- F2Pursuant to the Severance Agreement, on March 1, 2017, the Issuer issued 59,182 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 32,927 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.